Menu

Bones Get in Her Eyes

After undergoing untested cosmetic surgery that uses stem cells to rejuvenate skin, a woman grew bone fragments in the flesh around one of her eyes.

Dec 20, 2012
Dan Cossins

WIKIMEDIA, 8THSTARA Los Angeles woman who opted for an face-lift procedure involving adult stem cells ended up with fragments of bone embedded around her right eye, which made strange clicking noises and caused considerable pain. Reported this week in Scientific American, the case highlights the dangers of the untested stem cell-based cosmetic procedures that are becoming increasingly common in clinics around the United States.

The woman underwent the $20,000 surgery at a clinic in Beverley Hills in 2009. Surgeons isolated mesenchymal stem cells from her abdominal fat—cells that can become bone, cartilage, and fat, among other types of tissue—before injecting them into the skin around her eyes. The plan was that the stem cells would rejuvenate the skin by transforming into new skin tissue and releasing chemicals that stimulate other skin cells to proliferate.

But the surgeons also injected dermal filler, commonly used to reduce wrinkles. These fillers are made up largely of calcium hydroxylapatite, a mineral used by cell biologists to coax mesenchymal stem cells to become bone. This interaction likely resulted in the development of little pieces of bone in flesh around the woman’s eyes, the surgeon who three months later removed the fragments told Scientific American.

More and more clinics are now offering untested stem cell treatments for a range of cosmetic and medical procedures, and the overstretched US Food and Drug Administration is struggling to clamp down on all of them. Unapproved therapies are dangerous for consumers, and they could also make it more difficult for legitimate stem cell researchers to get funding as unscrupulous private clinics stigmatize the field.  

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.